Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes.

abstract：PURPOSE:Topotecan is widely used for refractory solid tumors but multi-drug resistance may occur due to tumor expression of ATP-binding cassette (ABC) transporters. Since erlotinib, an inhibitor of the epidermal growth factor receptor, also inhibits several ABC transporters, we performed a phase I study to evaluate the...

journal_title：Cancer chemotherapy and pharmacology

authors： Stewart CF,Tagen M,Schwartzberg LS,Blakely LJ,Tauer KW,Smiley LM

更新日期：2014-03-01 00:00:00

abstract：PURPOSE:The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced m...

journal_title：Cancer chemotherapy and pharmacology

authors： Spieth K,Kaufmann R,Gille J

更新日期：2003-11-01 00:00:00

abstract：BACKGROUND:Inhibitors of heat shock protein (Hsp) 90 induce apoptosis in multiple myeloma (MM) cells, but the molecular mechanisms underlying this cytotoxic outcome are not clear. Here, we investigate the effect of IPI-504, a novel and highly soluble inhibitor of the Hsp90 ATPase activity, on the unfolded protein respo...

journal_title：Cancer chemotherapy and pharmacology

authors： Patterson J,Palombella VJ,Fritz C,Normant E

更新日期：2008-05-01 00:00:00

abstract：PURPOSE:Folate receptor (FR) targeted drug conjugates were prepared by covalently attaching the vitamin folate, to the potent anticancer drug, mitomycin C (MMC). One such conjugate, called EC72, was synthesized with an intramolecular disulfide bond, and it was found to exhibit efficacious anti-tumor activity against FR...

journal_title：Cancer chemotherapy and pharmacology

authors： Reddy JA,Westrick E,Vlahov I,Howard SJ,Santhapuram HK,Leamon CP

更新日期：2006-08-01 00:00:00

abstract：:The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer. In all, 60 metastatic colorectal cancer patients with measurable disease...

journal_title：Cancer chemotherapy and pharmacology

authors： Kato T,Mishima H,Ikenaga M,Murata K,Ishida H,Fukunaga M,Ota H,Tominaga S,Ohnishi T,Amano M,Ikeda K,Ikeda M,Sekimoto M,Sakamoto J,Monden M

更新日期：2008-02-01 00:00:00

abstract：:Increasing the expression of human multidrug resistance (MDR) 1 gene in bone marrow cells to prevent or circumvent bone morrow toxicity from chemotherapy agent is a high priority of dose intensification protocols. In this study, we have used a tumor-bearing model to investigate the chemoprotection effect of MDR1 gene ...

journal_title：Cancer chemotherapy and pharmacology

authors： Guo CB,Li YC,Jin XQ

更新日期：2006-07-01 00:00:00

abstract：PURPOSE:To evaluate the safety and efficacy of the combination of cisplatin on day 1 and docetaxel on days 1, 8 and 15 every 4 weeks for the treatment of previously untreated patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:A group of 38 patients with advanced or metastatic NSCLC who had not rece...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsunoda T,Koizumi T,Hayasaka M,Hirai K,Koyama S,Takabayashi Y,Fujimoto K,Kubo K

更新日期：2004-08-01 00:00:00

abstract：:Previous studies have demonstrated that treatment with fludarabine 4 h prior to arabinosylcytosine (ara-C) potentiates the accumulation of the active triphosphate of ara-C (ara-CTP) in leukemic lymphocytes. The clinical efficacy of this combination was evaluated in 15 patients with chronic lymphocytic leukemia (CLL) t...

journal_title：Cancer chemotherapy and pharmacology

authors： Gandhi V,Robertson LE,Keating MJ,Plunkett W

更新日期：1994-01-01 00:00:00

abstract：BACKGROUND:Cancer has become one of the global health issues and it is the life-threatening disease characterized by unrestrained growth of cells. Despite various advances being adopted by chemotherapeutic management, the use of the current anticancer drugs such as Doxorubicin, Asparginase, Methotrexate, Vincristine re...

journal_title：Cancer chemotherapy and pharmacology

authors： Khanam R,Ahmad K,Hejazi II,Siddique IA,Kumar V,Bhat AR,Azam A,Athar F

更新日期：2017-11-01 00:00:00

abstract：PURPOSE:To compare serum and urine levels of tamoxifen and metabolites after a loading dose and at the steady state. METHODS:A loading dose of 160 mg of tamoxifen was given to 14 patients with advanced breast cancer. Thereafter a regular daily dose of 30 mg of tamoxifen was given. Serum and urine levels of tamoxifen a...

journal_title：Cancer chemotherapy and pharmacology

authors： de Vos D,Slee PH,Briggs RJ,Stevenson D

更新日期：1998-01-01 00:00:00

abstract：:Carmustine (BCNU) has proved to be of value against a variety of primary brain tumors. This agent exhibits a steep dose-response curve in in vitro and animal tumor models and has been proposed for use in high-dose chemotherapy as a single agent or in combination. We conducted a phase II study to assess high-dose BCNU ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bouffet E,Khelfaoui F,Philip I,Biron P,Brunat-Mentigny M,Philip T

更新日期：1997-01-01 00:00:00

abstract：BACKGROUND:We wished to define the maximum tolerated dose (MTD), toxicity, and pharmacokinetics of the novel isoflav-3-ene, NV06 (Phenoxodioltrade mark), a compound with a diphenolic structure related chemically and biologically to genistein and flavopiridol. PATIENTS AND METHODS:Twenty-one patients with advanced canc...

journal_title：Cancer chemotherapy and pharmacology

authors： de Souza PL,Liauw W,Links M,Pirabhahar S,Kelly G,Howes LG

更新日期：2006-10-01 00:00:00

abstract：:The nephrotoxic interaction between cis-diamminedichloroplatinum (CDDP) and amikacin (AMI) was studied in rats. Following a single dose of CDDP (5 mg/kg i.v.), AMI (60 mg/kg s.c.) was given for 14 days. When given alone CDDP caused a 40% fall in the glomerular filtration rate (GFR), whereas AMI alone had no effect on ...

journal_title：Cancer chemotherapy and pharmacology

authors： Jongejan HT,Provoost AP,Molenaar JC

更新日期：1988-01-01 00:00:00

abstract：:Antibodies can be used to target cancer therapies to malignant tissue; the approach is attractive because conventional treatments such as chemo- and radiotherapy are dose limited due to toxicity in normal tissues. Effective targeting relies on appropriate pharmacokinetics of antibody-based therapeutics, ideally showin...

journal_title：Cancer chemotherapy and pharmacology

authors： Chester KA,Mayer A,Bhatia J,Robson L,Spencer DI,Cooke SP,Flynn AA,Sharma SK,Boxer G,Pedley RB,Begent RH

更新日期：2000-01-01 00:00:00

abstract：PURPOSE:We have previously reported that intra-arterial chemotherapy prolongs the survival of patients with advanced HCC (aHCC); however, whether the response to intra-arterial chemotherapy depends on the etiology of underlying liver cirrhosis (LC) is still unknown. AIM:The aim of this study was to assess any influenc...

journal_title：Cancer chemotherapy and pharmacology

authors： Kanayama M,Nagai H,Sumino Y

更新日期：2009-06-01 00:00:00

abstract：PURPOSE:The aim of this study was to investigate typical population pharmacokinetic (PK) parameters, potential covariates, and interindividual and residual variabilities of PI-88, a heparanase endoglycosidase enzyme inhibitor being developed for the treatment of cancer. METHODS:A population PK model of PI-88 was devel...

journal_title：Cancer chemotherapy and pharmacology

authors： Hudachek SF,Eckhardt SG,Hicks B,Gustafson DL

更新日期：2010-03-01 00:00:00

abstract：:All-trans retinoic acid (ATRA) induces a high incidence of complete remission (CR) in patients with acute promyelocytic leukemia (APL); however, the magnitude of this agent's contribution to increased rates of cure of this disease has not yet been established. From 1990 to 1995 we used RA as remission induction therap...

journal_title：Cancer chemotherapy and pharmacology

authors： Soignet S,Fleischauer A,Polyak T,Heller G,Warrell RP Jr

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:The aim of the study was to assess the clinical activity and toxicity of oxaliplatin and leucovorin in combination with bolus and continuous infusional 5-fluorouracil administered every 2 weeks (modified FOLFOX-6 regimen) to patients with adenocarcinoma of an unknown primary site (ACUP). METHODS:Previously unt...

journal_title：Cancer chemotherapy and pharmacology

authors： Shin DY,Choi YH,Lee HR,Na II,Yuh YJ,Kim BS,Chung IJ,Bae WK,Shim HJ,Song EK,Yang SH,Kang HJ

更新日期：2016-01-01 00:00:00

abstract：PURPOSE:To investigate the synergistic cytotoxicity of TRAIL in combination with chemotherapeutic agents in A549 cell lines, we systematically evaluated the cytotoxicity of TRAIL alone and TRAIL in combination with cisplatin, paclitaxel (Taxol) or actinomycin D in A549 cell lines in vitro and in vivo, and whether the s...

journal_title：Cancer chemotherapy and pharmacology

authors： Fan QL,Zou WY,Song LH,Wei W

更新日期：2005-02-01 00:00:00

abstract：PURPOSE:S-1 and gemcitabine (GS) combination therapy is a promising treatment for advanced biliary tract cancer (BTC). However, systemic administration of GS is associated with a high rate of grade 3 and 4 neutropenia. Hepatic arterial infusion (HAI) of gemcitabine may overcome this problem. We conducted a prospective ...

journal_title：Cancer chemotherapy and pharmacology

authors： Ishiwatari H,Hayashi T,Yoshida M,Ono M,Sato T,Miyanishi K,Sato Y,Takimoto R,Kobune M,Kato J

更新日期：2015-04-01 00:00:00

abstract：:The present paper reviews several studies performed between 1977 and 1986 in Singapore on the 10-year survival outcome of treatment for stage I and II hepatocellular carcinoma (HCC). Of 801 HCC patients evaluated, only 2 survivors (0.3%) remained in complete remission for 13 and 14 years, respectively. One had receive...

journal_title：Cancer chemotherapy and pharmacology

authors： Oon CJ

更新日期：1992-01-01 00:00:00

abstract：:All-trans-retinoic acid (ATRA) has been incorporated in front-line therapy for newly diagnosed acute promyelocytic leukemia (APL). We conducted a multicenter study of differentiation therapy with ATRA alone or in combination with chemotherapy followed by intensive postremission chemotherapy in patients with APL (the J...

journal_title：Cancer chemotherapy and pharmacology

authors： Asou N,Adachi K,Tamura U,Kanamaru A,Kageyama S,Hiraoka A,Omoto E,Akiyama H,Tsubaki K,Saito K,Kuriyama K,Oh H,Kitano K,Miyawaki S,Takeyama U,Yamada O,Nishikawa K,Takahashi M,Matsuda S,Ohtake H,Ohno R

更新日期：2001-08-01 00:00:00

abstract：PURPOSE:To investigate the activity and tolerance of pegylated liposomal doxorubicin in combination with vinorelbine in pretreated patients with metastatic breast cancer. PATIENTS AND TREATMENT:Thirty-six women with metastatic breast cancer were enrolled. The median age was 64 years, 80% of the patients had a performa...

journal_title：Cancer chemotherapy and pharmacology

authors： Ardavanis A,Mavroudis D,Kalbakis K,Malamos N,Syrigos K,Vamvakas L,Kotsakis A,Kentepozidis N,Kouroussis C,Agelaki S,Georgoulias V,Breast Cancer Committee of the Hellenic Oncology Research Group.

更新日期：2006-12-01 00:00:00

abstract：PURPOSE:ABT-888 inhibits poly(ADP-ribose) polymerase (PARP) and may enhance the efficacy of chemotherapy and radiation in CNS tumors. We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of ABT-888 in a non-human primate (NHP) model that is highly predictive of human CSF penetration. METHODS:ABT-8...

journal_title：Cancer chemotherapy and pharmacology

authors： Muscal JA,Thompson PA,Giranda VL,Dayton BD,Bauch J,Horton T,McGuffey L,Nuchtern JG,Dauser RC,Gibson BW,Blaney SM,Su JM

更新日期：2010-02-01 00:00:00

abstract：PURPOSE:For the development of a safe and effective dual inhibitor of anticancer drug efflux transporters P-glycoprotein and multidrug resistance protein 1 (MRP1) to conquer multidrug resistance, we investigated the effects of dietary phytochemicals on the functions of P-glycoprotein and MRP1. METHODS:The effects of d...

journal_title：Cancer chemotherapy and pharmacology

authors： Nabekura T,Yamaki T,Ueno K,Kitagawa S

更新日期：2008-10-01 00:00:00

abstract：:Axitinib is approved with indication in patients with advanced renal cell carcinoma (RCC). Due to the localization of this cancer, physicians sometimes have to deal with hemodialyzed patients. Data exploring hemodialysis (HD) impact on axitinib pharmacokinetic (PK) or safety are lacking. To date, no data have been pub...

journal_title：Cancer chemotherapy and pharmacology

authors： Thiery-Vuillemin A,Orillard E,Mouillet G,Calcagno F,Devillard N,Bouchet S,Royer B

更新日期：2017-06-01 00:00:00

abstract：INTRODUCTION:Hormone-refractory disseminated prostate cancer is a major oncological problem. Preclinical studies with temozolomide, an oral alkylating agent, in prostate cancer have shown encouraging results. In phase I studies the safety of temozolomide in non-prostate cancer patients has been demonstrated. Based on t...

journal_title：Cancer chemotherapy and pharmacology

authors： van Brussel JP,Busstra MB,Lang MS,Catsburg T,Schröder FH,Mickisch GH

更新日期：2000-01-01 00:00:00

abstract：PURPOSE:Temozolomide pharmacokinetics were evaluated in children receiving concurrent O(6)-benzylguanine (O(6)BG), which enhanced the hematological toxicity of temozolomide. METHODS:Temozolomide was administered orally, daily for 5 days starting at 28 mg/m(2) per day with escalations to 40, 55, 75 and 100 mg/m(2) per ...

journal_title：Cancer chemotherapy and pharmacology

authors： Meany HJ,Warren KE,Fox E,Cole DE,Aikin AA,Balis FM

更新日期：2009-12-01 00:00:00

abstract：PURPOSE:Chemosensitizers such as cyclosporin A can increase intracellular accumulation of chemotherapeutic agents such as Adriamycin in certain multidrug-resistant (MDR) cell lines with overexpression of P-glycoprotein. It is likely that, when combined with cyclosporin A, hyperthermia could increase membrane permeabili...

journal_title：Cancer chemotherapy and pharmacology

authors： Larrivée B,Averill DA

更新日期：2000-01-01 00:00:00

abstract：:The effects of heat on intracellular accumulation of anthracyclines were investigated by laser flow cytometry analysis. Sarcoma-180 cells were exposed to Adriamycin (ADM), epirubicin (EPIR), daunomycin (DM), THP-Adriamycin (THP), ME-2303 (ME) and KRN-8602 (KRN) at 37 degrees C and at higher temperatures. There was a d...

journal_title：Cancer chemotherapy and pharmacology

authors： Sakaguchi Y,Maehara Y,Inutsuka S,Takahashi I,Yoshida M,Emi Y,Baba H,Sugimachi K

更新日期：1994-01-01 00:00:00